氨基胍预防SDT大鼠增生性糖尿病视网膜病变和白内障的研究

Fumihiko Toyoda, A. Kakehashi, Ayumi Ota, Nozomi Kinoshita, C. Kambara, H. Yamagami, H. Tamemoto, H. Ueba, Y. Dobashi, S. Ishikawa, M. Kawakami, Y. Kanazawa
{"title":"氨基胍预防SDT大鼠增生性糖尿病视网膜病变和白内障的研究","authors":"Fumihiko Toyoda, A. Kakehashi, Ayumi Ota, Nozomi Kinoshita, C. Kambara, H. Yamagami, H. Tamemoto, H. Ueba, Y. Dobashi, S. Ishikawa, M. Kawakami, Y. Kanazawa","doi":"10.2174/1876524601104010108","DOIUrl":null,"url":null,"abstract":"Advanced glycation end products (AGEs) play important roles in the development of ocular complications in diabetes mellitus. Spontaneously Diabetic Torii (SDT) rats have marked hyperglycemia and severe ocular complications. We evaluated the effect of anti-AGE agents, aminoguanidine and pyridoxamine, and an antioxidant, probucol, on the development of diabetic retinopathy (DR) and cataract in SDT rats. Experiment 1 included five SDT rats treated with aminoguanidine, four SDT rats treated with probucol, and four untreated control SDT rats. After age 55 weeks, we evaluated DR by fluorescein angiomicroscopy and pathological study and cataract by biomicroscopy. Experiment 2 included six SDT rats treated with pyridoxamine, and six SDT rats and 10 non-diabetic normal Sprague-Dawley (SD) rats not treated with pyridoxamine. Retinopathy and cataract were evaluated as in experiment 1. Urinary pentosidine and Maillard reaction product X (MRX) levels were measured for 40 weeks in each group. Experiment 1: Mature cataracts and DR developed in all untreated SDT rats; aminoguanidine prevented cataracts and DR (p<0.05, vs untreated SDT rats). Probucol had no effect. Experiment 2: Mature cataracts developed in all untreated SDT rats (p<0.001 vs normal SD rats (0/10)) and DR developed in 67% (p<0.01, vs normal SD rats (0/10, 0%)). Pyridoxamine did not prevent cataracts (6/6, 100�) or DR (4/6, 37%) (nonsignificant vs untreated SDT rats) in SDT rats. Urinary pentosidine levels were higher in untreated (0.12±0.07 μg/mgCre) and pyridoxamine-treated (0.12±0.05 μg/mgCre) SDT rats than normal SD rats (0.069±0.019 μg/mgCre), but not significantly so. Urinary MRX levels were significantly (p<0.01) lower in normal SD rats (17.5±9.6 μg/mgCre) compared with untreated SDT rats (163.0±107.0 μg/mgCre); pyridoxamine had no effect (149.0±66.5 μg/mgCre) (nonsignificant vs untreated SDT rats). Aminoguanidine but not pyridoxamine and probucol prevents DR and cataracts in SDT rats.","PeriodicalId":22762,"journal":{"name":"The Open Diabetes Journal","volume":"150 1","pages":"108-113"},"PeriodicalIF":0.0000,"publicationDate":"2011-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Prevention of Proliferative Diabetic Retinopathy and Cataract in SDT Rats with Aminoguanidine, an Anti-Advanced Glycation End Product Agent\",\"authors\":\"Fumihiko Toyoda, A. Kakehashi, Ayumi Ota, Nozomi Kinoshita, C. Kambara, H. Yamagami, H. Tamemoto, H. Ueba, Y. Dobashi, S. Ishikawa, M. Kawakami, Y. Kanazawa\",\"doi\":\"10.2174/1876524601104010108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advanced glycation end products (AGEs) play important roles in the development of ocular complications in diabetes mellitus. Spontaneously Diabetic Torii (SDT) rats have marked hyperglycemia and severe ocular complications. We evaluated the effect of anti-AGE agents, aminoguanidine and pyridoxamine, and an antioxidant, probucol, on the development of diabetic retinopathy (DR) and cataract in SDT rats. Experiment 1 included five SDT rats treated with aminoguanidine, four SDT rats treated with probucol, and four untreated control SDT rats. After age 55 weeks, we evaluated DR by fluorescein angiomicroscopy and pathological study and cataract by biomicroscopy. Experiment 2 included six SDT rats treated with pyridoxamine, and six SDT rats and 10 non-diabetic normal Sprague-Dawley (SD) rats not treated with pyridoxamine. Retinopathy and cataract were evaluated as in experiment 1. Urinary pentosidine and Maillard reaction product X (MRX) levels were measured for 40 weeks in each group. Experiment 1: Mature cataracts and DR developed in all untreated SDT rats; aminoguanidine prevented cataracts and DR (p<0.05, vs untreated SDT rats). Probucol had no effect. Experiment 2: Mature cataracts developed in all untreated SDT rats (p<0.001 vs normal SD rats (0/10)) and DR developed in 67% (p<0.01, vs normal SD rats (0/10, 0%)). Pyridoxamine did not prevent cataracts (6/6, 100�) or DR (4/6, 37%) (nonsignificant vs untreated SDT rats) in SDT rats. Urinary pentosidine levels were higher in untreated (0.12±0.07 μg/mgCre) and pyridoxamine-treated (0.12±0.05 μg/mgCre) SDT rats than normal SD rats (0.069±0.019 μg/mgCre), but not significantly so. Urinary MRX levels were significantly (p<0.01) lower in normal SD rats (17.5±9.6 μg/mgCre) compared with untreated SDT rats (163.0±107.0 μg/mgCre); pyridoxamine had no effect (149.0±66.5 μg/mgCre) (nonsignificant vs untreated SDT rats). Aminoguanidine but not pyridoxamine and probucol prevents DR and cataracts in SDT rats.\",\"PeriodicalId\":22762,\"journal\":{\"name\":\"The Open Diabetes Journal\",\"volume\":\"150 1\",\"pages\":\"108-113\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open Diabetes Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1876524601104010108\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Diabetes Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876524601104010108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

摘要

晚期糖基化终产物(AGEs)在糖尿病眼部并发症的发生中起着重要作用。自发性糖尿病Torii (SDT)大鼠有明显的高血糖和严重的眼部并发症。我们评估了抗age药物氨基胍和吡哆胺以及抗氧化剂普罗布考对SDT大鼠糖尿病视网膜病变(DR)和白内障发展的影响。实验1包括5只氨基胍组SDT大鼠、4只普罗布考组SDT大鼠和4只未处理的对照SDT大鼠。55周后,我们用荧光素血管显微检查和病理检查评估DR,用生物显微检查评估白内障。实验2包括6只给予吡哆沙胺治疗的SDT大鼠,6只SDT大鼠和10只未给予吡哆沙胺治疗的正常SD大鼠。视网膜病变和白内障评分与实验1相同。每组测定尿戊苷和美拉德反应产物X (MRX)水平,持续40周。实验1:所有未经SDT治疗的大鼠均出现成熟白内障和DR;氨基胍可预防白内障和DR (p<0.05)。普罗布考没有效果。实验2:所有未治疗的SDT大鼠发生成熟白内障(p<0.001,与正常SD大鼠(0/10)相比),67%发生DR (p<0.01,与正常SD大鼠(0/10,0%)相比)。Pyridoxamine不能预防SDT大鼠的白内障(6/ 6,100)或DR(4/ 6,37 %)(与未治疗的SDT大鼠相比无统计学意义)。未处理组(0.12±0.07 μg/mgCre)和吡哆沙胺组(0.12±0.05 μg/mgCre)尿戊苷水平高于正常SD大鼠(0.069±0.019 μg/mgCre),但差异不显著。正常SD大鼠尿MRX水平(17.5±9.6 μg/mgCre)明显低于未治疗SD大鼠(163.0±107.0 μg/mgCre) (p<0.01);吡哆沙明无影响(149.0±66.5 μg/mgCre)(与未治疗的SDT大鼠相比无显著性差异)。氨基胍对SDT大鼠DR和白内障有预防作用,而吡哆沙明和普罗布考无预防作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prevention of Proliferative Diabetic Retinopathy and Cataract in SDT Rats with Aminoguanidine, an Anti-Advanced Glycation End Product Agent
Advanced glycation end products (AGEs) play important roles in the development of ocular complications in diabetes mellitus. Spontaneously Diabetic Torii (SDT) rats have marked hyperglycemia and severe ocular complications. We evaluated the effect of anti-AGE agents, aminoguanidine and pyridoxamine, and an antioxidant, probucol, on the development of diabetic retinopathy (DR) and cataract in SDT rats. Experiment 1 included five SDT rats treated with aminoguanidine, four SDT rats treated with probucol, and four untreated control SDT rats. After age 55 weeks, we evaluated DR by fluorescein angiomicroscopy and pathological study and cataract by biomicroscopy. Experiment 2 included six SDT rats treated with pyridoxamine, and six SDT rats and 10 non-diabetic normal Sprague-Dawley (SD) rats not treated with pyridoxamine. Retinopathy and cataract were evaluated as in experiment 1. Urinary pentosidine and Maillard reaction product X (MRX) levels were measured for 40 weeks in each group. Experiment 1: Mature cataracts and DR developed in all untreated SDT rats; aminoguanidine prevented cataracts and DR (p<0.05, vs untreated SDT rats). Probucol had no effect. Experiment 2: Mature cataracts developed in all untreated SDT rats (p<0.001 vs normal SD rats (0/10)) and DR developed in 67% (p<0.01, vs normal SD rats (0/10, 0%)). Pyridoxamine did not prevent cataracts (6/6, 100�) or DR (4/6, 37%) (nonsignificant vs untreated SDT rats) in SDT rats. Urinary pentosidine levels were higher in untreated (0.12±0.07 μg/mgCre) and pyridoxamine-treated (0.12±0.05 μg/mgCre) SDT rats than normal SD rats (0.069±0.019 μg/mgCre), but not significantly so. Urinary MRX levels were significantly (p<0.01) lower in normal SD rats (17.5±9.6 μg/mgCre) compared with untreated SDT rats (163.0±107.0 μg/mgCre); pyridoxamine had no effect (149.0±66.5 μg/mgCre) (nonsignificant vs untreated SDT rats). Aminoguanidine but not pyridoxamine and probucol prevents DR and cataracts in SDT rats.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Gene Expression of GSK3 in Type II Diabetics Compared to Non-Diabetics (ex vivo) G6PC2 rs560887 Gene Variant is Associated with Fasting Blood Glucose in the Admixed Mexican Population Role of Vitamin D Receptor in Prediabetes To Tell or Not to Tell: Disclosure and Self-Management among Adults with Early-Onset Type 2 Diabetes: A Qualitative Study Assessment of Cardiovascular Disease Risk among Qatari Patients with Type 2 Diabetes Mellitus, Attending Primary Health Care Centers, 2014
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1